Charles W. Newton - 09 Mar 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Director
Signature
/s/ Esther Cho, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
09 Mar 2026
Net transactions value
$0
Form type
4
Filing time
11 Mar 2026, 16:39:18 UTC
Previous filing
22 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Newton Charles W. Director C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON /s/ Esther Cho, Attorney-in-Fact 11 Mar 2026 0001866219

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Award +13,215 $0.000000* 13,215 09 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Stock Option (Right to Buy) Award +14,788 $0.000000* 14,788 09 Mar 2026 Common Stock 14,788 $11.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on May 15, 2026, subject to the Reporting Person's continuous service through each such vesting date.
F2 The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on June 9, 2026, subject to the Reporting Person's continuous service through each such vesting date.